ストックスクリーナーアプリを入手
6.90
0.29%
0.02
アフターアワーズ：
6.91
0.010
+0.14%
Xeris Biopharma Holdings Inc (XERS) 最新ニュース
Xeris Biopharma Holdings Inc. (XERS) Q1 2026 Earnings: Surprise EPS Profitability Achieved Amid Mixed Market ReceptionDownward Estimate Revision - newsline.com
Jim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma - Insider Monkey
Xeris Pharmaceuticals, Inc. (XERS) stock price, news, quote and history - Yahoo Finance UK
Xeris Biopharma Stock (US98422E1038): Debt Exchange Targets $23 Million Of 8% Convertible Notes - AD HOC NEWS
XERS Receives Notice of Allowance for Patent on Keveyis - GuruFocus
Xeris Biopharma Holdings, Inc. (XERS) Latest Stock News & Headlines - Yahoo Finance
XERS Enters Exchange Agreements to Retire Convertible Notes - GuruFocus
Xeris receives patent allowance for Keveyis through 2039 By Investing.com - Investing.com Canada
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS® - lincolnjournal.com
Xeris Biopharma Announces Debt Exchange Agreement to Strengthen Balance Sheet - GuruFocus
Jim Cramer Discussed 15 Stocks, Including Broadcom, Netflix, and His Skepticism Toward Tech Stocks - Insider Monkey
XERS Q1 2026 Earnings: EPS Surprise of 217.65% Drives Stock HigherPre-Announcement Alert - newsline.com
Xeris Biopharma to Retire $23 Million of Convertible Notes Through Private Exchange - marketscreener.com
Xeris to retire $23M of convertible notes through exchange agreements - MSN
Xeris Biopharma Announces Private Exchange of Convertible Notes - BioSpace
Xeris Biopharma (XERS) Retires $23M in Convertible Notes Through Exchange - GuruFocus
Xeris Biopharma to retire $23 million in convertible notes - Investing.com
Xeris Biopharma (NASDAQ: XERS) to retire $23M of 8% notes in cash-and-stock deal - Stock Titan
fastest-growing companies - Crain's Chicago Business
Xeris Biopharma (XERS) Surges 4%: Breaking Past Key Support with Upward MomentumMoving Average Crossovers - newsline.com
XERS Q1 2026 Earnings: EPS Surprise of 217.65% Drives Positive MomentumCapex Guidance - newsline.com
Xeris Biopharma Holdings (XERS) Edges Higher with Steady Support Levels HoldingCall Dominated - newsline.com
Xeris Biopharma director John Johnson sells $91,422 in shares By Investing.com - Investing.com Australia
Xeris Biopharma director Dawn Halkuff sells $121,885 in company stock By Investing.com - Investing.com South Africa
Xeris Biopharma director John Johnson sells $91,422 in shares - Investing.com UK
Xeris Biopharma director Marla Persky sells $91,432 in shares - Investing.com UK
Xeris Biopharma director Marla Persky sells $91,432 in shares By Investing.com - Investing.com Australia
Xeris Biopharma director Bormann-Kennedy sells $97,507 in stock By Investing.com - Investing.com South Africa
Xeris Biopharma director Dawn Halkuff sells $121,885 in company stock - Investing.com
Xeris Biopharma (XERS) director awarded new RSU and stock option grants - Stock Titan
Xeris Biopharma (XERS) director logs stock sale and new equity grants - Stock Titan
Xeris Biopharma director Bormann-Kennedy sells $97,507 in stock - Investing.com
[Form 4] Xeris Biopharma Holdings, Inc. Insider Trading Activity - Stock Titan
Xeris Biopharma (XERS) director trades stock and receives new equity awards - Stock Titan
Xeris Biopharma (XERS) director gets equity grant and 10b5-1 share sale - Stock Titan
Xeris Biopharma (XERS) director receives new RSU and stock option grants - Stock Titan
Xeris Biopharma Shareholders Elect Directors and Ratify Auditor - TipRanks
[8-K] Xeris Biopharma Holdings, Inc. Reports Material Event - Stock Titan
[144] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
XERS: RECORLEV drives robust growth as pipeline and commercial expansion accelerate, with strong financials - TradingView
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Biopharma (XERS) officer sells 16,667 shares in Rule 10b5-1 trade - Stock Titan
XERS Q1 2026 Earnings: Surprise Profitability at Odds with Market SentimentGross Profit Margin - newsline.com
XERS Q1 2026 Earnings: EPS Beat Masks Cautious Outlook as Shares DipEarnings Yield Spread - newsline.com
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right (NASDAQ:XERS) - Seeking Alpha
2.11%
大文字化:
|
ボリューム (24 時間):